Evidence map›Paper›PMID 42474027›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

A Programmable Calcification Nanoplatform for Loco-Regional Calcification-Immune Hepatocellular Carcinoma Therapy.

Long Liu, Peng Li, Zhixiang Lu, Shuqin Xu, Juanjuan Wang, Kai Ma, Haodong Yu, Can Zhou, Hu Chen, Gang Liu and 2 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Long LiuShaanxi Province Center for Regenerative Medicine and Surgery Engineering Research, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.ORCID https://orcid.org/0000-0002-3473-2248
Peng LiInstitute of Regenerative and Reconstructive Medicine, Med-X Institute, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Zhixiang LuState Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Biology, School of Life Sciences, Xiamen University, Xiamen, China.
Shuqin XuShaanxi Province Center for Regenerative Medicine and Surgery Engineering Research, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Juanjuan WangShaanxi Province Center for Regenerative Medicine and Surgery Engineering Research, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Kai MaShaanxi Province Center for Regenerative Medicine and Surgery Engineering Research, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Haodong YuShaanxi Province Center for Regenerative Medicine and Surgery Engineering Research, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Can ZhouDepartment of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Hu ChenShaanxi Province Center for Regenerative Medicine and Surgery Engineering Research, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Gang LiuState Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Biology, School of Life Sciences, Xiamen University, Xiamen, China.
Yi LyuShaanxi Province Center for Regenerative Medicine and Surgery Engineering Research, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Shuang BaiShaanxi Province Center for Regenerative Medicine and Surgery Engineering Research, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Funding

Fundamental Research Funds for the Central Universities 20720240051Fundamental Research Funds for the Xi'an Jiaotong University xzy012024129Fundamental Research Funds for the Xi'an Jiaotong University xzy022024018Major State Basic Research Development Program of China 2023YFB3810003Major State Basic Research Development Program of China 2023YFF0713700National Natural Science Foundation of China 82402501Sanqin Talent Introduction Plan-Youth Project of Shaanxi Province KSQYC202402
6 · The paper itself

Abstract

Inducing tumor calcification is a promising strategy for disrupting cancer progression, yet achieving efficient biomineralization with synergistic antitumor effects remains challenging. Here, a programmable calcification nanoplatform (CaIM) is developed using in situ growth of calcium peroxide (CaO

Indexed as

calcium overloadin situ growth synthesisMCOLN2mitochondrial dysfunctiontumor calcification

Identifiers

PMID42474027
PMCPMC13383153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.